Evidence map›Paper›PMID 40258342›Full record

ArticlePublic health genomics2025

Reporting Modifications from the IMPACT-FH Study Using the FRAME-IS.

Christie Gilbert Klaczko, Nicole L Walters, Andrew Brangan, Mary P McGowan, Amy C Sturm, Alanna Kulchak Rahm, Gemme Campbell-Salome, Laney K Jones

Abstract read
In one paragraph

Article in Public health genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christie Gilbert KlaczkoDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.
Nicole L WaltersDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.
Andrew BranganDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.
Mary P McGowanFamily Heart Foundation, Fernandina Beach, Florida, USA.
Amy C SturmDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.
Alanna Kulchak RahmDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.
Gemme Campbell-SalomeDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.
Laney K JonesDepartment of Genomic Health, Research Institute, Geisinger, Danville, Pennsylvania, USA.

Funding

Identification Methods, Patient Activation, and Cascade Testing for FH: IMPACT-FHR01HL148246 · NHLBI · GEISINGER CLINIC · PI Ana Morales Reyes · 2019 to 2026
$5.2M
NHLBI NIH HHS R01 HL148246
6 · The paper itself

Abstract

introductionFamilial hypercholesterolemia (FH), a genetic condition that causes lifelong exposure to elevated LDL-cholesterol, can lead to severe life-threatening cardiac outcomes if untreated. Often undiagnosed, widespread implementation of FH screening programs is needed. The IMPACT-FH pragmatic research trial developed and tested a cascade testing program, which included three implementation strategies. Implementation strategies require modification across geographic locations and institutions.

methodsHere we report the modifications made throughout the IMPACT-FH cascade testing program for at-risk relatives of patients with FH from Geisinger's MyCode Community Health Initiative (MyCode®) and MyCode Genomic Screening and Counseling Program. The program was introduced to FH probands upon return of their genetically confirmed FH results from MyCode. The implementation strategies employed included an informational packet, chatbots, and direct contact. Modifications to the IMPACT-FH cascade testing program (intervention) and its implementation strategies were extracted from meeting recordings and interviews. We used FRAME-IS to code the nature, goal, timing, and impact of the changes on the program.

resultsIn total, eleven modifications were made. All modifications were initiated during the implementation phase of the study, were unplanned/reactive, and were made to optimize the fit of the program and strategies for FH probands and their families. Modifications were made to the overall IMPACT-FH cascade testing program (n = 3), the chatbot strategies (n = 3), and the direct contact strategy (n = 5). No modifications were made to the informational packet strategy.

conclusionsFlexibility and reactive modifications played a key role in the successful implementation of the cascade testing program within the IMPACT-FH pragmatic research trial.

Indexed as

Genetic TestingHyperlipoproteinemia Type IIFemaleHumansMaleCascade testingFamilial hypercholesterolemiaFamily communicationFRAME-ISImplementation scienceModification

Identifiers

PMID40258342
PMCPMC12167676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.